Decline in Tobacco and Alcohol Taxes in UK

Market by 2FIRSTS.ai
Jan.18.2024
Decline in Tobacco and Alcohol Taxes in UK
According to a recent analysis by financial experts RIFT, tobacco and alcohol tax in the UK has dropped at the fastest annual rate in two decades.

According to a January 17th report by British media outlet EINPresswire, the latest analysis from financial experts at RIFT suggests that the total amount of tobacco and alcohol tax received by the HM Revenue and Customs (HMRC) in the UK last year declined at the fastest annual rate in twenty years. Despite a continuous upward trend in tobacco and alcohol revenue during the same period, the data suggests that we may be seeing a trend of decreasing alcohol consumption and smoking habits.

 

RIFT has analyzed the latest data on tobacco and alcohol tax revenues from HMRC (up to December 2023), illustrating the changes in these tax revenues over the past 20 years and comparing them to NHS healthcare expenditures caused by smoking and alcohol consumption.

 

Analysis shows that the UK customs collected over £10 billion in tobacco taxes in the 2022/23 fiscal year. Although this is the second-highest total in the past twenty years, it signifies a 2.7% annual decrease, marking the third significant annual decline in two decades. Meanwhile, alcohol taxes paid in the 2022/23 fiscal year amounted to £12.4 billion, the highest total in the past 20 years. However, this represents a 5.1% annual decrease, the most severe single-year decline in two decades. Consequently, the total amount of taxes paid on tobacco and alcohol products last year reached £22.4 billion, despite the substantial sum, it indicates a 4% annual decrease, representing the largest annual reduction in the past 20 years.

 

This also marks the fourth consecutive year of decline in overall tobacco and alcohol tax revenues over the past two decades. Interestingly, in 2003/04, tobacco taxes accounted for 52% of HMRC's total income, but this proportion has now shifted, with alcohol taxes making up 55%. While smoking and drinking are detrimental to health, additional research by RIFT reveals that smoking-related medical expenses cost the NHS approximately £3.4 billion annually, whereas alcohol-related healthcare issues amount to £4.1 billion each year. Together, these expenses result in an expenditure of nearly £7.5 billion per year due to smoking and alcohol-related problems.

 

Although the figure itself is substantial, it only represents one-third of HMRC's total revenue from tobacco and alcohol taxes for the 2022/23 fiscal year.

 

RIFT General Manager Bradley Post commented, "Smoking and drinking are primary vices that many of us hope to quit, and we expect to begin the new year with a positive attitude. Currently, tobacco and alcohol tax revenues remain at their second-highest level in the past twenty years, generating approximately three times the estimated cost of medical services. However, both sources of tax revenue have seen the fastest decline in the past two decades.

 

One important issue to consider is the rise of e-cigarettes. Currently, e-cigarettes are not subject to the same taxation as tobacco products, although this situation may soon change. As a relatively new phenomenon, we do not yet know how many people choose to use e-cigarettes or what impact this will have on the NHS in the coming years.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
KT&G’s Lil Strengthens Market Lead in Korea as Heated Tobacco Share Reaches 47.4%
KT&G’s Lil Strengthens Market Lead in Korea as Heated Tobacco Share Reaches 47.4%
According to South Korea’s UpKorea, KT&G’s heated tobacco brand Lil reached a 47.4% share of Korea’s heated tobacco stick market in the first quarter of 2026. The company is expanding its next-generation products (NGP) business through product development, technology investment and overseas growth. KT&G reported NGP sales of 890.1 billion won (approximately US$650 million) in 2025, up significantly from 279.3 billion won in 2020. Lil products are now available in 34 markets, while KT&G continues building its technology portfolio through patents and multiple product platforms.
Jul.23
Product | JTI Expands Ploom Ecosystem as LYO Tobacco-Free Nicotine Sticks Roll Out Across Europe
Product | JTI Expands Ploom Ecosystem as LYO Tobacco-Free Nicotine Sticks Roll Out Across Europe
Japan Tobacco International (JTI) is expanding its Ploom heated product ecosystem with LYO tobacco-free nicotine sticks. Designed specifically for Ploom devices, LYO contains nicotine but no tobacco. Public information shows that the product has gradually entered several European markets, including Spain, Portugal and Germany, and was officially introduced in Romania in July 2026. The launch highlights JTI’s efforts to explore broader nicotine consumable formats beyond traditional tobacco-based sticks.
JTI
Jul.21 by 2Firsts Perspectives
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08